The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Private UK-based cell and gene therapy company Ixaka has announced positive interim results of its lead REX-001 drug candidate from a Phase III trial. 8 September 2021
US oncology specialist MacroGenics was trading 4% lower at lunchtime in the USA on Wednesday after presenting the final overall survival (OS) results of the SOPHIA Phase III in metastatic HER2-positive breast cancer. 8 September 2021
Indian drugmaker Hetero has announced that the Drug Controller General of India (DCGI) has issued for restricted use, Emergency Use Authorization (EUA) for the generic version of tocilizumab in India. 8 September 2021
Shares of USA-based biopharma Kadmon Holdings shot up nearly 74% to $9.21 pre-market today, after pharma major Sanofi revealed that it had reached agreement to acquire the company, which marks the fourth M&A deal for the French firm this year. 8 September 2021
Shares in Californian fibrosis specialist Pliant Therapeutics opened 14% higher on Tuesday, after the firm announced encouraging interim results from a Phase IIa trial. 8 September 2021
US drugmaker Amneal Pharmaceuticals has recently announced that its pipeline product IPX-203 (carbidopa + levodopa, (CD/LD)) achieved key primary and secondary endpoints in the pivotal Phase III RISE-PD clinical trial for patients with Parkinson’s disease (PD) who experience motor fluctuations. 8 September 2021
South Korea has recently decided to provide practical support to innovative pharmaceutical companies by revising the existing health insurance benefits system. 8 September 2021
The UK health technology assessor the National Institute of Health and Care Excellence (NICE) has reconsidered its previous decision for Erleada (apalutamide). 8 September 2021
Privately-held US early-stage gene therapy company NeuExcell Therapeutics and Spark Therapeutics, the gene therapy unit of Swiss pharma giant Roche Group, have entered a gene therapy collaboration aimed at developing a safe and effective treatment for patients suffering from Huntington's disease (HD). 8 September 2021
Netherlands-based AM-Pharma and Japan’s Kyowa Kirin have entered into an exclusive license agreement under which Kyowa Kirin gains the rights to develop and commercialize ilofotase alfa, AM-Pharma’s proprietary recombinant human alkaline phosphatase. 8 September 2021
For many years, politicians, patients and drugmakers alike have warned about the risk posed by growing antimicrobial resistance, spurred on by liberal use of antibiotics in farming, and in general medical practice. 8 September 2021
British cell therapy specialist Adaptimmune Therapeutics has entered into a strategic collaboration and license agreement with Genentech, a member of the Roche group. 7 September 2021
Global Blood Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted for filing and review two submissions relating to Oxbryta (voxelotor). 7 September 2021
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) today held a virtual press briefing with chief executives and top executives who are in the forefront of biopharmaceutical R&D for COVID-19. 7 September 2021
Sino-American company Brii Birosciences today announced that it is committing an additional $100 million to advance global regulatory filings and commercial efforts for its investigational SARS-CoV-2 (virus that causes COVID-19) combination therapy, BRII-196/BRII-198. 7 September 2021
US biotech BioMarin Pharmaceutical’s shares were down more than 10% at $76.25 pre-market today, after it announced on Sunday that the US Food and Drug Administration (FDA) placed a clinical hold on the BMN 307 Phearless Phase I/II study. 7 September 2021
A Scotland-based company that claims to be pioneering the future of modern medicine through microbiome-modulating therapeutics now has $21.5 million more to deliver on the promise. 7 September 2021
Medicines Australia, the leading trade group for the biotech and pharma industries in the country, has helped negotiate a five-year strategic plan with the national government. 7 September 2021
Blockbuster anti-PD-1 therapy Keytruda (pembrolizumab) has been approved by China’s National Medical Products Administration (NMPA) in combination with platinum- and fluoropyrimidine-based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus or gastroesophageal junction (GEJ). 7 September 2021